Sutro Biopharma

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell STRO and other ETFs, options, and stocks.

About STRO

Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. 

CEO
Jane Chung
CEOJane Chung
Employees
137
Employees137
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
2003
Founded2003
Employees
137
Employees137

STRO Key Statistics

Market cap
476.73M
Market cap476.73M
Price-Earnings ratio
-1.78
Price-Earnings ratio-1.78
Dividend yield
Dividend yield
Average volume
421.17K
Average volume421.17K
High today
$29.67
High today$29.67
Low today
$28.41
Low today$28.41
Open price
$29.63
Open price$29.63
Volume
209.73K
Volume209.73K
52 Week high
$43.85
52 Week high$43.85
52 Week low
$6.74
52 Week low$6.74

Stock Snapshot

The current Sutro Biopharma(STRO) stock price is $29.23, with a market capitalization of 476.73M. The stock trades at a price-to-earnings (P/E) ratio of -1.78.

During the trading session on 2026-05-31, Sutro Biopharma(STRO) shares reached a daily high of $29.67 and a low of $28.41. At a current price of $29.23, the stock is +2.9% higher than the low and still -1.5% under the high.

Trading activity shows a volume of 209.73K, compared to an average daily volume of 421.17K.

Over the past 52 weeks, Sutro Biopharma(STRO) stock has traded between a high of $43.85 and a low of $6.74.

Over the past 52 weeks, Sutro Biopharma(STRO) stock has traded between a high of $43.85 and a low of $6.74.

STRO News

Simply Wall St 3d
Industry Analysts Just Upgraded Their Sutro Biopharma, Inc. Revenue Forecasts By 46% - simplywall.st

...

Industry Analysts Just Upgraded Their Sutro Biopharma, Inc. Revenue Forecasts By 46% - simplywall.st
TipRanks 3d
Sutro Biopharma initiated with an Overweight at Barclays

Barclays initiated coverage of Sutro Biopharma (STRO) with an Overweight rating and $56 price target Sutro is a a biopharmaceutical company focused on the devel...

Analyst ratings

92%

of 13 ratings
Buy
92.3%
Hold
0%
Sell
7.7%

People also own

Based on the portfolios of people who own STRO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.